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EEG  phenotype  characterization  in a rat  substrain  related  to schizophrenia/autism.
ERPs  showed  signiﬁcant  changes  in  P2 latency  and  N1  amplitude.
Acute  ketamine  treatment  did not  cause  alterations  in  ERPs.
Altered  power  of oscillations  in  different  frequency  bands  was  observed.
Ketamine  caused  strain-dependent  changes  in  the  power  of  oscillations.
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Background:  Psychiatric  disorders  are  frequently  accompanied  by  changes  in brain  electrical  oscilla-
tions  and  abnormal  auditory  event  related  potentials.  The  goal  of  this  study  was  to  characterize  these
parameters  of a new  rat  substrain  showing  several  alterations  related  to schizophrenia.
Methods:  Male  rats  of  the  new  substrain,  developed  by selective  breeding  after  combined  subchronic
ketamine  treatment  and  postweaning  social  isolation,  and  naive  Wistar  ones  group-housed  without  any
interventions  were  involved  in  the  present  study.  At the  age  of  3 months,  animals  were  implanted  with
cortical  electroencephalography  electrodes.  Auditory  evoked  potentials  during  paired-click  stimuli  and
power  of  oscillation  in  different  frequency  bands  were  determined  with  and  without  acute  ketamine
(20  mg/kg)  treatment.
Results:  Regarding  the auditory  evoked  potentials,  the  latency  of P2  was  delayed  and  the  amplitude  of  N1
peak was  lower  in  the  new  substrain.  The  new  substrain  showed  increased  power  of  oscillations  in the
theta,  alpha  and  beta  bands,  while  decreased  power  was  detected  in  delta  and  gamma2  bands  (52–70  Hz)
compared  with  control  animals.  Acute  ketamine  treatment  increased  the gamma1  band  (30–48  Hz)  power
in both  groups,  while  it elicited  signiﬁcant  changes  only  in  the  new  substrain  in  the  total  power  and  in
alpha,  beta  and gamma2  bands.
Conclusions:  The  validation  of  the  translational  utility  of  this  new  rat  substrain  by electrophysiological
investigations  revealed  that these  rats  show  abnormalities  that may  model  a part  of the  neurophysiolog-
ical  deﬁcits  observed  in  schizophrenia.©  2016  Elsevier  B.V.  All  rights  reserved.Abbreviations: EEG, electroencephalography; ERP, event related potential; NMDAR, N
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. Introduction
Schizophrenia is a common neurodevelopmental and highly
eritable neuropsychiatric disorder [1,2]. Over the past few
ecades, researches using electroencephalography (EEG) have
dentiﬁed several neurophysiological alterations in this disease,
ndicating neural circuit disruptions. Unfortunately, the results are
ontroversial, and they may  depend on the subtype or phase of the
isease; therefore, its modeling in preclinical research ﬁeld is a big
hallenge [3–9]. It is argued that perfect simulation of inherently
uman diseases in animals might be impossible, but the recreation
f endophenotypes related to the disorders is a possibility. There-
ore, developing animal models with abnormal EEG activity may
elp in the clariﬁcation of the mechanisms in the background of this
europsychiatric disease [10,11]. Previous studies using different
odent models of schizophrenia showed widely diversiﬁed alter-
tions in the power of EEG oscillations and event related potentials
ERP) [12–23].
Preclinical and clinical studies focusing on pharmacological and
enomical changes support the hypothesis that hypofunction of N-
ethyl-d-aspartate receptor (NMDAR) signaling contributes to the
athophysiology of schizophrenia; therefore, NMDAR antagonists,
ncluding ketamine, have been used extensively to probe ques-
ions related to its neurobiology [24–28]. Ketamine administered to
ealthy controls in subanesthetic dose mimics several symptoms of
chizophrenia, and it worsens these signs in schizophrenia patients
24,29,30]. Furthermore, NMDAR antagonists or silencing of these
eceptors are used in animal models of neuropsychiatric disorders
howing several alterations in EEG activity, too [13,18,25,31–34].
We developed a complex animal model by selective breed-
ng based on behavioral alterations after combined subchronic
etamine treatment and postweaning social isolation [35,36]. It is
hought that selective breeding for phenotypic extremes increases
he homozygosity of genes that affect the selected trait, whereby
he allelic frequency of trait-irrelevant genes remains unaffected
37]. Therefore, animals selectively bred for a behavioral given
henotype are increasingly used to study pathophysiological mech-
nisms underlying certain disorders. For example, rats have been
uccessfully bred for anxiety [38], reduced sensorimotor gating [39]
nd for seizure susceptibility [40]. Several aspects of schizophre-
ia were found in the new substrain, i.e., disturbances in pain
ensitivity, sensory gating, memory functions, motor activity and
tereotypic behaviors [35,36]. Our recent data indicated that both
eritable and environmental factors (i.e., juvenile social isola-
ion and ketamine treatment) are important in the generation of
he behavioral alterations, but the most signiﬁcant changes were
bserved after the combination of treatments with selective breed-
ng [35,36,41]. In order to keep the number of animals used in the
xperiments at minimal level, we decided to compare two groups
f animals, i.e., naive rats without any intervention and the new
ubstrain after juvenile isolation and subchronic ketamine treat-
ent. In this report, the electrophysiological phenotype of this
ew rat substrain was characterized by the investigation of ERPs,
heir gating, and the basal frequency bands with and without acute
etamine treatment, to test the potential usefulness of the substrain
n studying the neurophysiological deﬁcits related to schizophre-
ia.
. MethodsAll experiments involving animal subjects were carried out
ith the approval of the Hungarian Ethics Committee for Animal
esearch (registration number: XIV/03285/2011). Animal suffering
nd the number of animals per group were kept to a minimum. Research 307 (2016) 65–72
2.1. Selective breeding process
The paradigm for selective breeding was  described previously
[35,36]. Brieﬂy, the parental generation consisted of male and
female (10-10) outbred Wistar rats. Offsprings of the rats in the next
generations were tested after weaning with the tail-ﬂick test (48 ◦C
hot water) to assess pain sensitivity, and then housed individu-
ally for 28 days. The animals were treated with ketamine (Calypsol,
Richter Gedeon Plc., Budapest, Hungary; 30 mg/kg IP, 4 mL/kg, daily,
5 times/week, 15 injections in total) from 5 to 7 weeks of age. Then
the animals were re-housed (4–5 rats/cage) and 1 week of recov-
ery was provided to them with no treatment. Starting at the age
of 9 weeks, the pain sensitivity, the sensory gating with prepulse
inhibition, and the cognitive functions and stereotypic behavior on
novel object cognition test were assessed (Table 1). Animals (5 male
with 10 female) with the highest level of disturbances in these
parameters were used for selective breeding throughout several
generations.
2.2. Experimental paradigm for EEG experiments
Two experimental groups of 8–8 rats were compared: naive
socialized male rats without any interventions; and the 17th gen-
eration of selectively bred male rats with social isolation and
ketamine treatment as new substrain. After the above-mentioned
behavioral tests, the animals were involved in the EEG experiments
(Table 1).
Rats were anesthetized with a mixture of ketamine hydrochlo-
ride and xylazine (72 and 8 mg/kg intraperitoneally, respectively),
and transferred into a stereotaxic frame. Afterwards, small burr
holes were drilled in their skull for electrode placement accord-
ing to coordinates found in the rat brain atlas [42]. The target area
for the epidural stainless steel electrodes and coordinates relative
to bregma were the following at both sides: recording electrodes:
parietal cortex 6 mm  posterior, 2 mm lateral to bregma; reference
electrodes: 1.5 mm posterior to bregma, 2 mm lateral, and a ground
electrode 2.5 mm posterior to bregma, 1 mm lateral. Finally, elec-
trodes were placed in a miniature 6-pin connector, which was ﬁxed
with dental cement.
After the surgery, the animals were injected with gentamycin
(10 mg/kg, subcutaneously) to prevent infection, and were housed
individually. They were allowed to recover for one week with a
12:12-h light–dark cycle, an ambient temperature regulated at
23 ◦C, water and food with ad libitum access.
On the testing days (between 8:00 AM and 12:00 PM), animals
were placed in the recording chamber (L: 34 cm,  W:  14.5 cm, H:
33.5 cm), recording cables were attached to commutators allowing
the free movement of the rats, and they were allowed to accom-
modate to the test environment for 10 min  while auditory stimuli
were not present.
Following the acclimatization, the 20 min  test session was  ini-
tiated. For generation of ERPs to the sensory gating paradigm, two
consecutive clicks (70 dB clicks with broad spectrum for 5 ms:  S1
and S2) were presented with interstimulus interval of 500 ms. The
interval between the pairs of clicks was  5 s. Clicks were driven by a
computer program and delivered via loudspeakers.
To habituate the animals to the task and to minimize the poten-
tial discomfort during the tests, three recording sessions were
performed on three consecutive weeks without any intervention.
Then EEG recordings were repeated after acute ketamine (20 mg/kg
intraperitoneally) or vehicle (saline) injection on the subsequent
two weeks. Each animal was  given both injections with 7 days
apart, and the order of vehicle and drug administration was coun-
terbalanced. After the injections, the rats were placed in their cage
for 20 min  before putting them to the recording chamber for EEG
registration.
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Table  1
Experimental paradigm.
Groups Age (weeks)
3 4 5–7 8 9 10 12 13–15 16–17
Naive rats
(n = 8)
New
substrain
(n = 8)
(PD21)
weaning TF
test 1
group
housing
social
isolation
social isola-
tion + ketamine
treatment
group
housing
TF test 2
PPI test
NOR test EEG
electrode
implanta-
tion + recovery
EEG for
habituation
EEG
registration
after acute
ketamine/saline
Abbreviations: PD—postnatal day; TF—tail-ﬂick; PPI—prepulse inhibition; NOR—novel ob
Fig. 1. Event related potentials (ERPs) using the paired-click paradigm.
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0verage of ERPs with SEM in naive and new substrain rats in response to the ﬁrst
S1) and the second (S2) auditory stimuli. Arrows denote stimulus onsets. P1, N1
nd  P2 refer to ERP-related peaks.
Bipolar EEG recordings were performed from both sides of the
kull. The signals were ampliﬁed with a custom made eight chan-
el EEG ampliﬁer (gain setting: 1000) by using AD8222 (Analog
evices Inc.) high performance instrumentation ampliﬁer. The sig-
als were online ﬁltered using the following ﬁlter settings: high
ass ﬁlter = 0.33 Hz; low pass ﬁlter = 155 Hz. The ampliﬁed and ﬁl-
ered signals were then digitized and recorded with a 16 channel
atawave system. The sampling rate of the electrophysiological sig-
als was 5 kHz. The recorded EEG signals were stored on a computer
or subsequent ofﬂine analysis.
.3. Data analysis
We  calculated the averaged ERP in response to S1 and S2 to
easure the amplitudes, latencies of the responses and their gating.
The P1, N1 and P2 components were identiﬁed accordingly:
1 was the ﬁrst positive-going wave that occurs in the range of
0–45 ms  after stimulus, the N1 component was the ﬁrst negative-
oing component directly following P1 in the range of 20–70 ms
fter stimulus, and P2 was the second positive-going wave that
ccurs between 40 and 100 ms  (Fig. 1). The amplitudes and the
atencies of each component were determined. Gating was  deﬁned
s the ratio of the peak-to-peak amplitudes of the corresponding
omponents recorded as the ﬁrst and second ERPs. Therefore, two
egments were calculated: the difference between P1 and N1 and
etween N1 and P2, and the magnitude of inhibition was deﬁned as
he ratio of the evoked responses (S2/S1) for both amplitudes (G1
nd G2).
Power density values were calculated by fast Fourier trans-
ormation (FFT) of artefact-free epochs under condition of
.61 Hz resolution with a Hanning window for 5 min  peri-(7 days) treatment
ject recognition; EEG—electroencephalogram.
ods before the auditory stimuli in the frequency range of
delta (0.6–4 Hz), theta (4–8 Hz), alpha (8–13 Hz), beta (13–30 Hz)
and gamma1 (30–48 Hz), gamma2 (52–70 Hz) and gamma3
(71–100 Hz) bins/waves. Relative band powers were expressed as
power ratios of each frequency band to the total (z-score).
The obtained EEG data were analyzed off-line with Datawave
system (DataWave Technologies, Loveland, CO, USA) and Spike2
(Cambridge Electronic Design, Cambridge, UK) systems. Data are
expressed as means ± SEM. Mean values of the different parameters
were compared with ANOVA, with factors group,  clicks and treat-
ment. When the global test was signiﬁcant, the LSD post hoc test
was used for the evaluation of the effects of the various parameters.
Statistical analysis was performed with Statistica 11.0 software
(Statsoft, Tulsa, Oklahoma, USA). Differences were considered sig-
niﬁcant for p < 0.05.
3. Results
3.1. Behavioral alterations
In agreement with our recent studies [35,36], the naive and new
substrain rats involved in the EEG experiments showed signiﬁ-
cant differences on the behavioral tests. Thus, the new substrain
showed blunted pain sensitivity detected at the age of 3 and 9
weeks: ANOVA revealed signiﬁcant effects of group (F(1,14) = 12.53;
p < 0.05) and time (F(1,14) = 87.20; p < 0.0001) with signiﬁcantly
longer latencies in the new substrain at week 9. Impaired sen-
sory gating on the prepulse-inhibition test was also present:
ANOVA revealed a signiﬁcant effect of group (F(1,14) = 5.99; p < 0.05)
with lower values in the new substrain. ANOVA showed that the
new substrain spent signiﬁcantly less time with the exploration
of the new object compared to the naive ones (F(1,14) = 11.73,
p < 0.005) in the novel object recognition test. Furthermore, the
grooming activity of the new substrain was  signiﬁcantly higher
(F(1,14) = 5.92, p < 0.05) that was  accompanied by lower rearing
activity (F(1,14) = 10.71, p < 0.01).
Qualitative observations indicated that the rats had mild impair-
ments in coordination and locomotor activity following acute
ketamine treatment during the EEG recordings.
3.2. Analysis of ERP responses
Regarding the latency of P1 and N1 peaks, there were no signif-
icant differences between the groups, the treatments, the ﬁrst and
second clicks and their interactions (data are not shown). Regard-
ing the latency of P2, ANOVA showed a signiﬁcant effect of group
(F(1,28) = 14.99; p < 0.001), thus the new substrain had longer laten-
cies compared to the control group, but neither ketamine treatment
nor the order of the clicks inﬂuenced it (Fig. 2A).
The second click induced lower amplitudes of all the peaks com-
pared to the ﬁrst one in both groups, and this decrease was  not
inﬂuenced by acute ketamine treatment. Regarding the differences
between the two  groups for both clicks no signiﬁcant differences
were observed in the amplitude of P1 and P2 peaks (data are not
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(ig. 2. Alterations in the peaks of event related potentials.
ean P2 latencies (A) and N1 amplitudes (B) to paired stimuli in naive and new sub
ompared to naive group. The symbol + denotes signiﬁcant differences between res
hown), but N1 peak was signiﬁcantly lower in the new substrain
ompared to the control one; thus, ANOVA showed a signiﬁcant
ffect of group (F(1,28) = 11.44; p < 0.005) (Fig. 2B).
As regards the degree of gating there was no signiﬁcant differ-
nce between the two groups in the G1 value (G1 naive: 0.53 ± 0.03
s. G1 new substrain: 0.51 ± 0.09), while G2 was higher in the con-
rol group, thus the degree of the gating was lower in these animals
G2 naive: 0.63 ± 0.04 vs. G2 new substrain: 0.49 ± 0.03; p < 0.05).
cute ketamine treatment had no signiﬁcant inﬂuence on these
arameters (G1 naive 0.55 ± 0.03 vs. G1 new substrain 0.42 ± 0.05;
nd G2 naive: 0.52 ± 0.04 vs. G2 new substrain: 0.48 ± 0.04).
.3. Oscillatory activity
As regards the total power of the waves, ANOVA showed a signif-
cant effect of group (F(1,28) = 9.15; p < 0.01). Post-hoc test revealed
hat the new substrain had signiﬁcantly higher total power after
etamine treatment compared to the control animals (Fig. 3A).
Regarding the delta band, ANOVA showed a signiﬁcant effect of
roup (F(1,28) = 8.84; p < 0.01); thus, the new substrain had lower
ower in this frequency band, while ketamine did not inﬂuence
igniﬁcantly this parameter in either group (Fig. 3B).
As regards the theta band, ANOVA showed a signiﬁcant effect of
roup (F(1,28) = 6.12; p < 0.05; alpha); therefore, the new substrain
ad higher power in this frequency band without ketamine treat-
ent, but ketamine decreased the differences between the two
roups (Fig. 3B).
As regards the alpha band, ANOVA showed a signiﬁcant effect of
roup (F(1,28) = 4.89; p < 0.05) and treatment (F(1,28) = 8.37; p < 0.01);
hus, the new substrain had higher power in this frequency band
hat was signiﬁcantly decreased by acute ketamine treatment
Fig. 3C).
As regards the beta band, ANOVA showed a signiﬁcant effect of
reatment (F(1,28) = 10.41; p < 0.005) and the group and treatment
nteraction (F(1,28) = 5.21; p < 0.05); therefore, the new substrain
ad higher power in this frequency band that was  signiﬁcantly
ecreased by acute ketamine treatment similarly to alpha band
Fig. 3C).As regards the gamma1 band, ANOVA showed a signiﬁcant effect
f treatment (F(1,28) = 11.81; p < 0.005), thus, acute ketamine injec-
ion signiﬁcantly increased the power of this band in both groups
Fig. 3D). rats after saline or ketamine treatment. The symbol * signs signiﬁcant differences
s to S1 and S2 stimuli.
As regards the gamma2 band, ANOVA showed a signiﬁcant effect
of treatment (F(1,28) = 5.45; p < 0.05) and the group and treatment
interaction (F(1,28) = 6.22; p < 0.05); therefore, the new substrain
had lower power in this frequency band that was signiﬁcantly
increased by acute ketamine treatment (Fig. 3D). As regards the
gamma3 waves, no signiﬁcant effects were observed (Fig. 3D).
4. Discussion
The electrophysiological validation of the translational utility
of this new rat substrain revealed that these animals showed sev-
eral neurophysiological abnormalities observed in schizophrenia.
The latency of the P2 peaks was prolonged, and the amplitude of
N1 response decreased; however, the gating was  not impaired in
these animals in the double-click paradigm. Furthermore, the acute
treatment with a subanesthetic dose of ketamine did not result
in signiﬁcant alterations in ERP parameters. The new substrain
showed increased power of oscillations in the theta, alpha and beta
ranges, while decreased power was detected in delta and gamma2
bands compared with the control animals. Ketamine treatment
increased the gamma1 band power in both groups, while it caused
signiﬁcant changes only in the new substrain in the total power
and in alpha, beta and gamma2 bands, suggesting the enhanced
sensitivity for this drug.
Paired-click paradigm is a standard method used to assess
sensory gating [43]. ERP in human studies has a positive deﬂec-
tion occurring approximately 50 ms  following the onset of sensory
stimulation (P50), which is generated primarily in the auditory tha-
lamus and temporal cortex [44,45]. The N100 component, a large
negative deﬂection, occurs following the P50 response originated
mainly from the primary auditory cortex [46]. The second posi-
tive deﬂection that emerges approximately 200 ms  after sensory
stimulation (P200) is generated by the association cortex reﬂect-
ing higher-order integration and interpretation of sensory stimuli.
The ERP waveforms obtained in rodents show very similar char-
acteristics to human ones with the exception that the latencies of
the rodent ERP are signiﬁcantly shorter [4]. Thus, ERPs in rodent
typically show a positive deﬂection between 10 and 30 ms  (P1),
a negative deﬂection between 30 and 50 ms  (N1), and a second
positive deﬂection between 50 and 100 ms (P2) (Fig. 1).
Reduced peak amplitudes of the auditory ERP are well repli-
cated in schizophrenic patients [43,45,46], and have been observed
in multiple relevant rodent models [19], but no changes in
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Fig. 3. Basal EEG power in different frequency bands.
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ands;  (D) gamma1-3 bands. * Signs signiﬁcant differences compared to naive gr
reatments.
hese parameters were also reported [44,46]. Ketamine exposure
ecreased the amplitude of ERP in several human and animal stud-
es [12,21,34,46,47], but contradictory results are also available
48]; the latter is in agreement with our results. It seems that
he P50 responses have limited utilities as a clinical or research
ool; however, reduction in N100 amplitude is widely reported
n schizophrenia as an endophenotype with a strong heritability,
epresenting deﬁcits in initial sensory processing and early atten-
ion [46]. Therefore, the change in N1 peak amplitude in rodents
ay  be a potential biomarker for schizophrenia that has been
etected in disease-relevant transgenic mice and also induced by
cute ketamine treatment [43,46,48]. The decreased N1 response,
bserved in our substrain, is in agreement with these studies, which
uggests that this substrain may  simulate schizophrenia in this
espect. Amplitude of the P200/P2 is reduced in schizophrenia, after
cute exposure to ketamine in healthy controls and rodents, how-
ver, we did not detect it in our substrain, which might be due to
he differences in the applied dose or the strain [46].
EEG recordings in healthy humans exhibit habituation to
epeated stimuli; thus the amplitude of the auditory evoked
otential is markedly attenuated upon the second click stimulus
ompared with the ﬁrst one [5,44,45]. The sensory gating paradigm
as been frequently used to study neurophysiological processes
n schizophrenia, however, ERP-based sensory gating ﬁndings inetamine treatment. (A) Total power; (B) delta and theta bands; (C) alpha and beta
he symbol # denotes signiﬁcant differences between acute saline and ketamine
this disease are somehow diverse; several studies show deﬁcits
[4,45,46,49,50], while some are negative, as it was  found in the
new substrain [51–53]. The ineffectivity of both acute and chronic
ketamine treatment on the ERP gating, in agreement with our data,
indicates that NMDA receptors may  not be critically involved in
its generation [12,47,54–56]. Altogether, the alterations observed
in the ERPs in our substrain showed limited correlation with the
human schizophrenic data (decreased amplitude of N1).
Several neural oscillatory abnormalities have been demon-
strated in schizophrenia that may  contribute to the abnormal
sensory and cognitive performance [1,3,7–9,46,57,58]. Neural
oscillations depend on the kinetics of inhibitory (GABAergic) and
excitatory (glutamatergic) synaptic interactions, and the ineffec-
tive inhibitory control of sensory processing is characteristic in
this disease [3,16,17,47,59–61]. Because of the prominent role
of gamma-band activity in cognition during normal brain func-
tioning, there has been a particular focus on the investigation of
high-frequency activity in patient populations [46]. Fast-spiking,
parvalbumin-positive GABAergic neurons play a pivotal role in the
primary generation of high-frequency oscillations and their syn-
chronization, whereas glutamatergic pyramidal neurons appear
to control their strength, duration, and long-range synchroniza-
tion acting primarily via NMDARs [3,18,32,46,59,61]. Many human
studies observed reduced gamma  oscillatory activity, which may
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eﬂect the deﬁcits in cognitive and sensory processing related
o negative symptoms in schizophrenia [3,47,57,62,63]. How-
ver, there are controversial ﬁnding of increased gamma  activities
n schizophrenia as well, and it is reportedly relevant to posi-
ive symptoms (hallucination, delusion) [9,25,64–67]. Abnormal
amma  activity has been reported in numerous animal models of
chizophrenia, too, e.g., silencing of the GABAergic interneurons
nd hypofunction of NMDAR signaling is accompanied by altered
scillatory power particularly in the gamma  range [17,32,46,68].
hronic NMDAR antagonist treatment may  cause decreased oscil-
atory power several weeks or months after the cessation of the
reatment, suggesting long-lasting consequences of such an inter-
ention [12,21,69]. Thus, the decreased gamma  power between 52
nd 70 Hz in our new substrain might be due, at least partially,
o chronic ketamine treatment. Regarding the acute drug effect,
n agreement with our results, signiﬁcantly elevated gamma  band
scillations have been observed in both human and animal studies,
eﬂecting a cortical hyperglutamatergic state through GABAergic
isinhibition, leading to a mild shift in the excitation/inhibition
alance toward excitation [12,16,47,58,70–73].
Beta oscillations, less explored in schizophrenia, are believed
o be generated broadly across multiple neocortical structures and
re involved in the adaptation to repetitive sensory stimuli, atten-
ion, and synchronization of large ensembles of neurons [3,46]. In
greement with results observed in the new substrain, beta band
ower increases in patients with schizophrenia, which may  be
ue to global cortical hyperexcitability or attention disturbances
bserved in these patients [74]. As regards the alpha band oscilla-
ion, it is related primarily to the thalamus; thus, the alterations in
his frequency band may  suggest dysfunction of the inhibitory tha-
amic neurons [74,75]. Different laboratories have reported either
igher alpha power associated with negative symptoms [46,66,74]
r reduced alpha band power in a phase-independent manner
46,74], thus the enhanced power observed in our new substrain
ight be related to the negative symptoms of schizophrenia.
Abnormalities in lower frequency oscillations (delta and theta)
re also prominent in this disease [7,8,76,77]. The cortical delta
and oscillation originates from the reticular nucleus of the
halamus, where predominantly parvalbumin-positive GABAer-
ic neurons are present [78]. They can be partially but tonically
ctivated via NMDARs, thereby regulating the activity of thala-
ic  relay neurons projecting to the prefrontal cortex. The theta
requency range is associated with cognition/memory function,
here cortico-hippocampal circuits are key generators of the
hythm [59]. Both delta and theta band changes depend on the
hase of schizophrenia, i.e., patients with positive signs show no-
hanges or decrease in these parameters, while in negative phase
f schizophrenia increases were detected [25,65,66,74,77]. Our
odel showed decreased delta activity, which might simulate the
ositive phase of schizophrenia, while the enhanced theta power
an indicate the negative one. In contrast to our ﬁndings, most
tudies show signiﬁcantly reduced low-frequency oscillations after
cute ketamine treatment [12,16,47,58,69–73], and this discrep-
ncy might be explained by the differences in the applied doses.
As any rodent model of a complex human neuropsychiatric
isorder, our model has a number of shortcomings. The het-
rogeneity of this disease and the overlap in several aspects
ith other neuropsychiatric diseases, especially autism, further
omplicates the ability to discern the speciﬁcity of a given pre-
linical model [60,79,80]. Although autism and schizophrenia
re clearly distinct disorders, they share a signiﬁcant number
f common clinical characteristics, including genetics, epidemi-
logy (e.g., prenatal infection, maternal stress, and perinatal
ypoxia), behavioral phenotypes (e.g., impairments in social
nd cognitive behaviors, communicative function, and stereo-
yped behaviors), neuroimaging and neurophysiological ﬁndings Research 307 (2016) 65–72
(e.g., interneuron dysfunction or disrupted excitation/inhibition
balance) [1,60,79,81,82]. Furthermore, hypofunction of N-methyl-
d-aspartate receptor (NMDAR) signaling contributes to the
pathophysiology of both diseases [83–85]. NMDAR1 hypomor-
phic mice display both schizophrenia- and autism-like changes
in social and cognitive behaviors and in the oscillatory activity
[13,18,32–34]. Most of the behavioral alterations observed in this
new substrain can also be detected in autism [81,86–88], sim-
ilarly, the observed electrophysiological changes in our model
might simulate several alterations detected in both the autism and
schizophrenia and may  contribute to the abnormal sensory and
cognitive performance [1,3,7–9,46,57,58]. Especially, the signiﬁ-
cantly enhanced latency in the P2 responses in the new substrain
correlates with human studies involving autistic patients and its
animal models without inﬂuencing peak amplitude [18,85,89–91].
Since most of the abnormalities overlap in these two disor-
ders, these alterations regarding the EEG oscillations should be
accompanied by other more speciﬁc signs for relevant diagnosis
[1,17,18,32,46,60,68,74,82,85,90,92,93].
5. Conclusion
Our substrain was  originally developed as a complex model
of schizophrenia, and has been extensively investigated as such;
however, the results indicated that these rats exhibited several
autism-like behavioral and neurophysiological phenotypic alter-
ations. It also highlights the challenge of modeling a complex
human behavioral disorder in rodents, since as it was mentioned
above, most of these biomarkers are non-speciﬁc to these diseases.
It can be concluded that this substrain produces long-lasting alter-
ations on ERP and EEG oscillations after juvenile social isolation
and subchronic ketamine treatment. These results are partially in
agreement with clinical data, which suggests that this model pro-
vides a limited representation of disturbances observed in EEG of
schizophrenic and/or autistic patients. Although the strengths and
weaknesses of this model should be evaluated in the future by
molecular biological methods, too, we  conclude that our model
may  provide additional opportunity for the translational research
of these neuropsychiatric disorders.
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